-- Sanofi unveils heart disease partnership with MyoKardia
-- By James Regan
-- Wed Sep 17, 2014 01:22AM EDT
-- None



PARIS, Sept 17 (Reuters) - French drugmaker Sanofi <SASY.PA> announced on Wednesday a partnership with U.S.-based MyoKardia to develop therapies for patients with genetic heart diseases.

The collaboration includes up to $200 million in equity investments, milestone payments, and research and development services through 2018, Sanofi said in a statement.